CurrentEndo
Get Weekly

CurrentEndo coverage · page 35 of 55

Diabetes, Obesity and Metabolism

Briefs 1,361–1,400 of 2,200 CurrentEndo has covered from this journal, newest publication first

Latest from Diabetes, Obesity and Metabolism

All coverage, newest first

  1. Diabetes Obes Metab

    The effect of the endothelin receptor antagonist atrasentan on insulin resistance in phenotypic clusters of patients with type 2 diabetes and chronic kidney disease

    Secondary analysisT2D & other

  2. Diabetes Obes Metab

    Association and mediation pathways of maternal hyperglycaemia and liability to gestational diabetes with neonatal outcomes: A two‐sample Mendelian randomization study

    Research articleDiabetes in pregnancy

  3. Diabetes Obes Metab

    Benefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes—A real‐world study

    Cohort studyT2D & other

  4. Diabetes Obes Metab

    Non‐clinical and first‐in‐human characterization of ECC5004 / AZD5004 , a novel once‐daily, oral small‐molecule GLP ‐1 receptor agonist

    Mechanistic studyT2D & other

  5. Diabetes Obes Metab

    Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from the SURMOUNT ‐1 study

    Secondary analysisObesity

  6. Diabetes Obes Metab

    The impact of metabolic heterogeneity of obesity and transitions on cardiovascular disease incidence in Chinese middle‐aged and elderly population: A nationwide prospective cohort study

    Cohort studyObesity

  7. Diabetes Obes Metab

    Cost‐utility analysis of once‐weekly insulin icodec and once‐daily insulin glargine in patients with type 2 diabetes receiving basal‐bolus insulin therapy in China

    Research articleT2D & other

  8. Diabetes Obes Metab

    A Mediterranean dietary pattern intervention does not improve cardiometabolic risk but does improve quality of life and body composition in an Aotearoa New Zealand population at increased cardiometabolic risk: A randomised controlled trial

    Randomized controlled trialT2D & other

  9. Diabetes Obes Metab

    Subphenotypes of adult‐onset diabetes: Data‐driven clustering in the population‐based KORA cohort

    Cohort studyT2D & other

  10. Diabetes Obes Metab

    Dietary potassium intake and its interaction with sodium intake on risk of developing cardiovascular disease in persons with type 2 diabetes: The Japan Diabetes Complication and its Prevention Prospective study ( JDCP study 12)

    Cohort studyT2D & other

  11. Diabetes Obes Metab

    Body weight variability as a predictor of cardiovascular outcomes in type 1 diabetes: A nationwide cohort study

    Cohort studyT1D

  12. Diabetes Obes Metab

    Effect of spironolactone wash‐out on albuminuria after long‐term treatment in individuals with type 2 diabetes and high risk of kidney disease—An observational follow‐up of the PRIORITY study

    Randomized controlled trialComplications

  13. Diabetes Obes Metab

    Visit‐to‐visit HbA1c variability and risk of potentially avoidable hospitalisations in adults with type 2 diabetes receiving outpatient care at a tertiary hospital

    Cohort studyT2D & other

  14. Diabetes Obes Metab

    Graded association of muscle strength with all‐cause and cause‐specific mortality in older adults with diabetes: Prospective cohort study across 28 countries

    Cohort studyT2D & other

  15. Diabetes Obes Metab

    Characterizing body composition modifying effects of a glucagon‐like peptide 1 receptor‐based agonist: A meta‐analysis

    Meta-analysisT2D & other

  16. Diabetes Obes Metab

    Association of initial serum sodium change and clinical outcome in patients with diabetes receiving sodium–glucose cotransporter‐2 inhibitor therapy: A multicentre database analysis in Taiwan

    Cohort studyT2D & other

  17. Diabetes Obes Metab

    Body mass index trajectories and time in target range after delivery and long‐term type 2 diabetes risk in women with a history of gestational diabetes mellitus

    Cohort studyDiabetes in pregnancy

  18. Diabetes Obes Metab

    Association between delay in diabetes development and mortality in people with obesity: Up to 33 years follow‐up of the prospective Swedish Obese Subjects study

    Cohort studyObesity

  19. Diabetes Obes Metab

    The associations between functional vitamin K status and all‐cause mortality, cardiovascular disease and end‐stage kidney disease in persons with type 1 diabetes

    Cohort studyComplications

  20. Diabetes Obes Metab

    Efficacy and safety of cofrogliptin once every 2 weeks in Chinese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, phase 3 trial

    Randomized controlled trialT2D & other

  21. Diabetes Obes Metab

    Synergies between diabetes and hyperhomocysteinaemia: New insights to predict and prevent adverse cardiovascular effects

    Cohort studyT2D & other

  22. Diabetes Obes Metab

    The effect of sarcopenic obesity on glycaemic status based on fasting plasma glucose and glycated haemoglobin: A prospective cohort study

    Cohort studyObesity

  23. Diabetes Obes Metab

    Trends in anti‐diabetic medication use, severe hyperglycaemia and severe hypoglycaemia among American Indian and Alaska Native Peoples, 2009–2013

    Cohort studyT2D & other

  24. Diabetes Obes Metab

    Superior benefits of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors for diabetic kidney disease: A cohort study

    Cohort studyComplications

  25. Diabetes Obes Metab

    Effectiveness and safety of insulin glargine 300 U/mL in insulin‐naïve individuals according to diabetes duration: Results from the REALI European pooled data analysis

    Secondary analysisT2D & other

  26. Diabetes Obes Metab

    Low‐calorie, high‐protein diets, regardless of protein source, improve glucose metabolism and cardiometabolic profiles in subjects with prediabetes or type 2 diabetes and overweight or obesity

    Randomized controlled trialT2D & other

  27. Diabetes Obes Metab

    Association of non‐high‐density lipoprotein cholesterol/high‐density lipoprotein cholesterol ratio with cardiovascular outcomes in patients with type 2 diabetes mellitus: Evidence from the ACCORD cohort

    Cohort studyT2D & other

  28. Diabetes Obes Metab

    Evaluation of an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose‐ranging, phase 2, randomized, placebo‐controlled study

    Randomized controlled trialT2D & other

  29. Diabetes Obes Metab

    Lifelong impacts of puberty timing on human plasma metabolic profiles: A metabolome‐wide Mendelian randomization study

    Research article

  30. Diabetes Obes Metab

    In vivo mapping of postprandial hepatic glucose metabolism using dynamic magnetic resonance spectroscopy combined with stable isotope flux analysis in Roux‐en‐Y gastric bypass adults and non‐operated controls: A case–control study

    Research articleObesity

  31. Diabetes Obes Metab

    Metformin continuation post‐metabolic bariatric surgery and relapse of diabetes

    Cohort studyT2D & other

  32. Diabetes Obes Metab

    Genetic influences, lifestyle and psychosocial aspects in relation to metabolically healthy obesity and conversion to a metabolically unhealthy state

    Cohort studyObesity

  33. Diabetes Obes Metab

    Glycaemic outcomes in adults with type 2 diabetes over 34 weeks with the Omnipod® 5 Automated Insulin Delivery System

    Research articleTechnology

  34. Diabetes Obes Metab

    Cost‐effectiveness of finerenone added to standard of care for patients with type 2 diabetes‐related chronic kidney disease in the United States

    Research articleComplications

  35. Diabetes Obes Metab

    Relationship of high‐density lipoprotein subfractions and apolipoprotein A‐I with fat in the pancreas

    Cross-sectional study

  36. Diabetes Obes Metab

    A randomized phase I study of BI 1820237, a novel neuropeptide Y receptor type 2 agonist, alone or in combination with low‐dose liraglutide in otherwise healthy men with overweight or obesity

    Randomized controlled trialObesity

  37. Diabetes Obes Metab

    Efficacy and safety of a fixed‐dose combination of dapagliflozin and linagliptin ( AJU ‐ A51 ) in patients with type 2 diabetes mellitus: A multicentre, randomized, double‐blind, parallel‐group, placebo‐controlled phase III study

    Randomized controlled trialT2D & other

  38. Diabetes Obes Metab

    Semaglutide in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: A prospective, observational, open‐label study

    Cohort studyObesity

  39. Diabetes Obes Metab

    Somatic and mental symptoms associated with dysglycaemia, diabetes‐related complications and mental conditions in people with diabetes: Assessments in daily life using continuous glucose monitoring and ecological momentary assessment

    Cohort studyTechnology

  40. Diabetes Obes Metab

    Integrated approach of machine learning, Mendelian randomization and experimental validation for biomarker discovery in diabetic nephropathy

    Diagnostic or prognostic studyComplications

All 2,200 Briefs in ExploreShowing Briefs 1,361–1,400 of 2,200, newest first